Michelle Sarcinelli

Dr. Michelle Sarcinelli

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
BPBeatriz Ferreira Carvalho de Patricio
Beatriz Ferreira Carvalho de Patricio
MAMarta Souza de Albernaz
Marta Souza de Albernaz
MSMichelle Sarcinelli
Michelle Sarcinelli
SCSamira Marques de Carvalho
Samira Marques de Carvalho
RSRalph Santos-Oliveira
Ralph Santos-Oliveira
GWGilberto Weissmüller
Gilberto Weissmüller
Bone metastasis is responsible for up to 99% of bone tumors. As no cure has yet to be discovered, available treatments simply strive to improve quality of life. One of such treatments is the use of EDTMP (ethylenediamine-tetramethylenephosphonic acid) labeled with Samarium-153, which has been shown to improve survival in 70-80% of patients treated. A major disadvantage of this radiopharmaceutical is its superficial delivery, resulting in the need for multiple doses. The current work describes novel polymeric nanoparticles of EDTMP and evaluation of their biodistribution in vivo. Nanoparticles were prepared using a double emulsion-solvent evaporation method and characterized by AFM (atomic force microscopy). Nanoparticles (200-500 nm) were then labeled with Technetium-99m for biodistribution analysis in healthy Wistar rats. Polymeric nanoparticles of EDTMP were observed to accumulate at bone tissue for long periods of time (150 min), resulting in prolonged release of EDTMP at the target site. This finding suggests that this novel pharmaceutical formulation of EDTMP provides better targeted delivery than free EDTMP and may be a more optimal treatment for management of bone metastasis pain.

1 October 2014 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
SPSuyene Rocha Pinto
Suyene Rocha Pinto
MSMichelle Sarcinelli
Michelle Sarcinelli
MAMarta de Souza Albernaz
Marta de Souza Albernaz
FSFranciana Maria Rosa da Silva
Franciana Maria Rosa da Silva
SSSergio Henrique Seabra
Sergio Henrique Seabra
RSRalph Santos-Oliveira
Ralph Santos-Oliveira

1 September 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
RSRalph Santos-Oliveira
Ralph Santos-Oliveira
MAMarta de Souza Albernaz
Marta de Souza Albernaz
Marzena SzwedMarzena Szwed
Marzena Szwed
AIAlexandre Iscaife
Alexandre Iscaife
KLKatia Ramos Moreira Leite
Katia Ramos Moreira Leite
MSMichelle Sarcinelli
Michelle Sarcinelli
Monoclonal antibodies as polymeric nanoparticles are quite interesting and endow this new drug category with many advantages, especially by reducing the number of adverse reactions and, in the case of radiopharmaceuticals, also reducing the amount of radiation (dose) administered to the patient. In this study, a nanoradiopharmaceutical was developed using polylactic acid (PLA)/polyvinyl alcohol (PVA)/montmorillonite (MMT)/trastuzumab nanoparticles labeled with technetium-99m (99mTc) for breast cancer imaging. In order to confirm the nanoparticle formation, atomic force microscopy and dynamic light scattering were performed. Cytotoxicity of the nanoparticle and biodistribution with 99mTc in healthy and inducted animals were also measured. The results from atomic force microscopy showed that the nanoparticles were spherical, with a size range of ~200–500 nm. The dynamic light scattering analysis demonstrated that over 90% of the nanoparticles produced had a size of 287 nm with a zeta potential of -14,6 mV. The cytotoxicity results demonstrated that the nanoparticles were capable of reaching breast cancer cells. The biodistribution data demonstrated that the PLA/PVA/MMT/trastuzumab nanoparticles labeled with 99mTc have great renal clearance and also a high uptake by the lesion, as ~45% of the PLA/PVA/MMT/trastuzumab nanoparticles injected were taken up by the lesion. The data support PLA/PVA/MMT/trastuzumab labeled with 99mTc nanoparticles as nanoradiopharmaceuticals for breast cancer imaging.

9 February 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
ASAndressa Daniele Artico Silva
Andressa Daniele Artico Silva
MSMichelle Sarcinelli
Michelle Sarcinelli
BPBeatriz Ferreira de Carvalho Patricio
Beatriz Ferreira de Carvalho Patricio
MCMarcelo Henrique da Cunha Chaves
Marcelo Henrique da Cunha Chaves
LLLeandro Martins Lima
Leandro Martins Lima
HRHelvécio Vinícius Antunes Rocha
Helvécio Vinícius Antunes Rocha

3 January 2024 in Beilstein Journal of Nanotechnology
Verified
Journal Article
Open access
PDF file
LCLucas Carvalho
Lucas Carvalho
MSMichelle Sarcinelli
Michelle Sarcinelli
BPBeatriz Patrício
Beatriz Patrício
Schistosomiasis causes over 200,000 deaths annually. The current treatment option, praziquantel, presents limitations, including low bioavailability and resistance. In this context, nanoparticles have emerged as a promising option for improving schistosomiasis treatment. Several narrative reviews have been published on this topic. Unfortunately, the lack of clear methodologies presented in these reviews leads to the exclusion of many important studies without apparent justification. This integrative review aims to examine works published in this area with a precise and reproducible method. To achieve this, three databases (i.e., Pubmed, Web of Science, and Scopus) were searched from March 31, 2022, to March 31, 2023. The search results included only original research articles that used nanoparticles smaller than 1 µm in the treatment context. Additionally, a search was conducted in the references of the identified articles to retrieve works that could not be found solely using the original search formula. As a result, 65 articles that met the established criteria were identified. Inorganic and polymeric nanoparticles were the most prevalent nanosystems used. Gold was the primary material used to produce inorganic nanoparticles, while poly(lactic-co-glycolic acid) and chitosan were commonly used to produce polymeric nanoparticles. None of these identified works presented results in the clinical phase. Finally, based on our findings, the outlook appears favorable, as there is a significant diversity of new substances with schistosomicidal potential. However, financial efforts are required to advance these nanoformulations.

1 June 2021 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MSMichelle Sarcinelli
Michelle Sarcinelli
TSThalita Martins da Silva
Thalita Martins da Silva
ASAndressa Daniele Artico Silva
Andressa Daniele Artico Silva
BPBeatriz Ferreira de Carvalho Patricio
Beatriz Ferreira de Carvalho Patricio
FPFlávia Costa Mendes de Paiva
Flávia Costa Mendes de Paiva
HRHelvécio Vinícius Antunes Rocha
Helvécio Vinícius Antunes Rocha